



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

25 September 2024  
EMA/421953/2024  
Press office

## Recommendations on eligibility to PRIME scheme

Adopted at the CHMP meeting of 16-19 September 2024

During its September 2024 meeting, the CHMP reviewed 2 recommendations for eligibility to PRIME and 2 were denied. The individual outcomes adopted this month are listed below.

---

**Official address** Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

**Address for visits and deliveries** Refer to [www.ema.europa.eu/how-to-find-us](http://www.ema.europa.eu/how-to-find-us)

**Send us a question** Go to [www.ema.europa.eu/contact](http://www.ema.europa.eu/contact) **Telephone** +31 (0)88 781 6000

An agency of the European Union



© European Medicines Agency, 2024. Reproduction is authorised provided the source is acknowledged.


## Eligibility denied

Product type	Therapeutic area	Therapeutic indication	Type of data supporting request	Type of applicant
Biological Medicinal Product	Congenital, familial and genetic disorders	Treatment of Adenosine Triphosphate Binding Cassette Transporter Protein Subfamily C Member 6 (ABCC6) Deficiency	Non-clinical + clinical exploratory	Other
<i>Chemical Product</i>	<i>Musculoskeletal and connective tissue disorders</i>	<i>Treatment of Osteoarthritis</i>	<i>Non-clinical + Tolerability first in man</i>	<i>SME</i>

SME applicants are micro-, small-and medium-sized-enterprises registered with the Agency's SME office. Other type of applicants are those not qualifying or not registered as SME or not fulfilling the definition of academic sponsors.

# Cumulative overview of PRIME eligibility recommendations adopted by 19 September 2024

■ Granted
 ■ Denied
 ■ Out of scope\*
 ■ Withdrawn
 ■ Transition\*\*



\* This indicates eligibility requests received but not started by EMA as they were deemed outside the scope of the scheme or with a format and content inadequate to support their review. These are not included in the breakdown by type of applicant or by therapeutic area.

\*\* Application for transition from Early Entry to Full PRIME eligibility.